Drug Treatment of Motor Symptoms in Parkinson's Disease
Reference158 articles.
1. Agnati LF, Leo G, Vergoni AV, Martinez E, Hockemeyer J, et al. 2004. Neuroprotective effect of l-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res Bull 64: 155–164.
2. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, et al. 1997. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63: 421–428.
3. Battistin L, Bardin PG, Ferro-Milone F, Ravenna C, Toso V, et al. 1999. Alpha-dihydroergocryptine in Parkinson's disease: A multicentre randomized double blind parallel group study. Acta Neurol Scand 99: 36–42.
4. Beal MF. 1998. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol 44: S110–S114.
5. Ben Shlomo Y, Marmot MG. 1995. Survival and cause of death in a cohort of patients with parkinsonism: Possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293–299.